Healthcare Industry News: HSMN NewsFeed
News Release - September 6, 2011
Regeneron Announces Appointment of Joseph J. LaRosa as Senior Vice President, General Counsel and SecretaryTARRYTOWN, N.Y., Sept. 6, 2011 -- (Healthcare Sales & Marketing Network) -- Regeneron Pharmaceuticals, Inc. (Nasdaq:REGN ) today announced that Joseph J. LaRosa has been appointed Senior Vice President, General Counsel and Secretary. Mr. LaRosa will be responsible for overseeing all of the Company's legal affairs, including general corporate legal matters, intellectual property and corporate compliance, and will report to Leonard S. Schleifer, M.D., Ph.D., president and chief executive officer.
"We are extremely pleased to have recruited a seasoned corporate attorney with deep senior-level pharmaceutical experience to lead this important function," said Dr. Schleifer. "Joe's track record managing a variety of key legal functions at Schering-Plough and Nycomed will be directly relevant as Regeneron, which now employs more than 1,600 people, continues to build its product portfolio and the capabilities of a fully integrated pharmaceutical company."
Previously, Mr. LaRosa held a number of senior legal positions at Schering-Plough Corporation, where he was a corporate officer and served most recently as Vice President, Legal Affairs, and a member of the Operations Management Team. He also served as Vice President, Global Compliance and Legal Affairs at Avon Products, Inc. Most recently Mr. LaRosa was Senior Vice President, General Counsel and Secretary at Nycomed US Inc.
"I am excited to join the Regeneron senior management team at a time when the company is emerging as one of the best-positioned biotechnology companies," said Mr. LaRosa, who holds undergraduate and J.D. degrees from New York University. "Regeneron is known for outstanding science and innovative collaborations with leading pharmaceutical companies, and in recent years it has also demonstrated its abilities in clinical development, manufacturing, and commercialization of new biotechnology-based drugs."
About Regeneron Pharmaceuticals
Regeneron is a fully integrated biopharmaceutical company that discovers, develops, manufacturers, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, which is approved for the treatment of a rare inflammatory condition, Regeneron has completed Phase 3 clinical trials of rilonacept for a new indication and of product candidates EYLEA™ (aflibercept injection; VEGF Trap Eye) in diseases of the eye and ZALTRAP® (aflibercept) (VEGF Trap) in colorectal cancer. EYLEA is currently under review with U.S. and European regulatory authorities. Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis, pain, cholesterol reduction, allergic and immune conditions, and cancer. Additional information about Regeneron and recent news releases are available on www.regeneron.com.
Source: Regeneron Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsSanofi and Regeneron Announce FDA Approval of Dupixent(R) (dupilumab), the First Targeted Biologic Therapy for Adults with Moderate-to-Severe Atopic Dermatitis
Kevzara(TM) (sarilumab) now available in Canada for the Treatment of Adult Patients with Moderately to Severely Active Rheumatoid Arthritis
Appeals Court Grants Stay of Permanent Injunction for Praluent(R) (alirocumab) During Appeals Process